Clinical Trials
10 trialsNCT01597388 2026-02-24
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
AstraZeneca
Phase 1 Completed
NCT02208375 2025-12-31
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
NCT02398747 2024-12-17
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02193633 2024-09-26
TAX-TORC
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT02599714 2024-06-06
PASTOR
AstraZeneca
Phase 1 Completed
NCT02619864 2023-08-04
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT02064608 2019-07-17
CaNCaP02
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Completed
NCT02780830 2016-09-15
INHIBITOR
AstraZeneca
Phase 1 Withdrawn
NCT01026402 2016-02-11
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
AstraZeneca
Phase 1 Completed